Neuralink, the brain-technology company co-founded by Elon Musk, is set to launch its first international clinical trial.
The company has received approval from Health Canada to conduct the CAN-PRIME Study, according to a Nov. 20 news release. This study aims to evaluate the safety of Neuralink's implant and surgical robot while testing the effectiveness of its brain-computer interface (BCI).
The BCI is designed to enable individuals with quadriplegia to control external devices using their thoughts. The trial is open to Canadian residents with limited or no use of both hands due to ALS or cervical spinal cord injury.